<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230821059204N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-12</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Dextrose Injection in Rotator Cuff Tendinopathy of The Shoulder</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72829</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In the first group, 2 ml of 25% dextrose Prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) and in the second group 2 ml of 12.5% dextrose Prolotherapy solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected. The control group will be exercise therapy, Randomization description: Randomization will be done using computer generated random numbers. Based on the selected numbers, the participants will be assigned to a 12.5% hypertonic dextrose prolotherapy group, another 25% hypertonic dextrose prolotherapy group, and a control group of exercise therapy.</study_design>
      <phase>3</phase>
      <hc_freetext>Rotator cuff tendinopathy of the shoulder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 25% Prolotherapy dextrose solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) will be injected. Intervention 2: Intervention group 2: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected. Intervention 3: Control group: The control group will be given exercise therapy, which exercises will be given to the patient in a booklet, and they will be taught in each visit that the exercises in the first week include correcting the position of the scapula and the shrug of the scapula; in the second week includes external rotation at zero degrees; In the third week, it includes internal rotation at 0 degrees, and in the fourth week, it includes boat movement at 45 degrees, boat movement at 90 degrees, anterior shoulder stretching and trunk stretching in a sitting position.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hanieh Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sports Medicine Department, Mostafavian Clinic, Razi No. 3 Alley, Razi St.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4816868890</zip>
        <telephone>+98 11 3336 6552</telephone>
        <email>H.ahmadi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hanieh Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sports Medicine Department, Mostafavian Clinic, Razi No. 3 Alley, Razi St.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4816868890</zip>
        <telephone>+98 11 3336 6552</telephone>
        <email>H.ahmadi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults (over 20 years)
Chronic shoulder pain for more than six months
Shoulder ultrasound of the supraspinatus tendon showing chronic tendinopathy such as a tear or tendinosis
The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale (VAS)
Agreeing and complying with our study protocol
The possibility of signing an informed consent form</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Associated with adhesive capsulitis and limited range of motion of the shoulder
Shoulder joint replacement
Shoulder surgery or arthroscopy of the injured shoulder within the past year
Injection of steroid, hyaluronic acid or platelet-rich plasma or any type of prolotherapy injection in the shoulder joint within the last three months
Neurological disease that causes weakness on the affected side
Impaired cognitive function and inability to complete the questionnaire
Concurrent participation in another clinical trial</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S46.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 25% Prolotherapy dextrose solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) will be injected.</i_keyword>
      <i_keyword>Intervention group 2: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected.</i_keyword>
      <i_keyword>Control group: The control group will be given exercise therapy, which exercises will be given to the patient in a booklet, and they will be taught in each visit that the exercises in the first week include correcting the position of the scapula and the shrug of the scapula; in the second week includes external rotation at zero degrees; In the third week, it includes internal rotation at 0 degrees, and in the fourth week, it includes boat movement at 45 degrees, boat movement at 90 degrees, anterior shoulder stretching and trunk stretching in a sitting position.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Average score in the Shoulder Pain and Disability Index (SPADI) of the injured shoulder. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: The Shoulder Pain and Disability Index (SPADI) is a self-administered assessment tool used to measure shoulder pain and disability. It has five pain items and eight disability items measured on the Visual Analogue Score. Pain and disability subscales are calculated as the mean of the corresponding items on a 0-100 scale, with the highest score indicating the most severe pain and disability. In this study, the total outcome score used for statistical analysis will be calculated as the sum of pain and disability subscales.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Active range of motion of the shoulder. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: Active shoulder range of motion, i.e., forward flexion, internal rotation, external rotation, and abduction in standing position, will be assessed using a goniometer. Patients will move their shoulders slowly until they reach an angle at which pain is felt, and this movement will be performed three times to record the average value of the angle.</sec_outcome>
      <sec_outcome>Supraspinatus tendon thickness. Timepoint: At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention. Method of measurement: Using ultrasound, the maximum thickness of the supraspinatus tendon will be measured in millimeters.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-19</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences, Imam Hospital</contact_name>
        <contact_address>Serah Joibar, the beginning of Vali Asr Highway, the headquarters of Mazandaran University of Medical Sciences and Health Services Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
